The Global Antibiotic Resistance Partnership (GARP) aims to address the challenge of antibiotic resistance by developing actionable Policy Proposals in Vietnam and four other low- and middle-income countries: China, India, Kenya and South Africa. GARP will develop the evidence base for Policy action on antibiotic resistance and identify policy opportunities where research, advocacy and information have the best chance of slowing the development and spread of resistance

Poster

Las infecciones relacionadas con la atención sanitaria (IRAS) plantean una seria carga de enfermedad y tienen un efecto económico considerable en los pacientes y en los sistemas sanitarios de todo el mundo. Sin embargo, la higiene de las manos, la simple tarea de limpiarse las manos en los momentos adecuados y de la forma adecuada, puede salvar vidas

Folleto

Les infections associées aux soins (IAS) constituent une menace sérieuse dont l’impact économique pour les patients et les systèmes de santé dans le monde entier est significatif. Pourtant, la pratique de l’hygiène des mains – le simple fait d’assurer l’antisepsie des mains au moment opportun et de manière appropriée – permettrait de sauver des vies

Historically, the discovery of the sulfa drugs in the 1930s and the subsequent development of penicillin during World War II ushered in a new era in the treatment of infectious diseases. Infections that were common causes of death and disease in the pre-antibiotic era - rheumatic fever, syphilis, cellulitis and bacterial pneumonia - became treatable, and over the next 20 years most of the classes of antibiotics that find clinical use today were discovered and changed medicine in a profound way. The availability of antibiotics enabled revolutionary medical interventions such as cancer chemotherapy, organ transplants and essentially all major invasive surgeries from joint replacements to coronary bypass. Antibiotics, though, are unique among drugs in that their use precipitates their obsolescence. Paradoxically, these cures select for organisms that can evade them, fueling an arms race between microbes, clinicians and drug discoverers. Wright BMC Biology 2010, 8:123 http://www.biomedcentral.com/1741-7007/8/1

Strengthening Parmaceutical Systems. 2nd edition

2e edition